Netris pancreatic cancer study doses first patient
Company’s candidate NP137 combined with mFOLFIRINOX will be researched during vital trials - News - PharmaTimes
Source: pharmatimes.com
Stay updated with breaking news from Netris . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company’s candidate NP137 combined with mFOLFIRINOX will be researched during vital trials - News - PharmaTimes
Trial will evaluate efficacy of anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev - News - PharmaTimes